Torrent Pharmaceuticals LtdNSE: TORNTPHARM
Open the Torrent Pharmaceuticals Ltd page
Follow Torrent Pharmaceuticals LtdFree account. Get a note when Torrent Pharmaceuticals Ltd files.
Q1 FY27 results analysis · July 31, 2026

Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY27 Results Analysis: EBITDA Margin Expands 130 bps, Revenue Surges 17%

+3.3%PAT year on year, Rs. 566.00 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Torrent Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,921.00 Cr (+54.80% YoY) and PAT growth of +3.30% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 30, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 4,921.00 Cr (+54.80% YoY)
PAT (Q1)Rs. 566.00 Cr (+3.30% YoY)
EBITDA margin33.80% (+130 bps YoY)
EPS (Q1)Rs. 14.87 (-8.15% YoY)
Market capRs. 185,319.02 Cr
CMPRs. 4,872.10

Quarter Snapshot

Base business revenue grew 17% YoY, ahead of the 10-15% guidance, and consolidated EBITDA margin expanded 130 bps YoY to 33.8%. The JB Pharma acquisition delivered a 35.3% EBITDA margin, well above the guided 28-29% range, indicating faster-than-expected synergy realization. However, PAT growth was muted at 3.3% due to elevated finance costs and depreciation, and Germany business continued to decline 24% YoY due to supply disruption.

Key Investment Insights

Key Positives

  • Base business revenue grew 17% YoY to Rs.3,720 Cr, ahead of the 10-15% guidance band.
  • Consolidated EBITDA margin expanded 130 bps YoY to 33.8%, the highest in reported periods.
  • JB Business EBITDA margin improved to 35.3% from 28.8% in Q1 FY26, beating the guided 28-29% range.
  • India base business grew 19% YoY, outpacing IPM growth of ~12%, indicating market share gains.
  • Net worth more than doubled to Rs.17,848 Cr due to the JB Pharma amalgamation, improving debt/equity from 1.76x to 0.82x.

Risk Factors

  • PAT to owners grew only 3.3% YoY despite revenue growth of 54.8%, as finance costs (Rs.305 Cr, +444.6% YoY) and D&A (Rs.593 Cr, +195.0% YoY) from the JB acquisition absorbed incremental revenue.
  • Germany business (Others) declined 24% YoY to Rs.112 Cr due to persistent supply disruption, continuing for third consecutive quarter.
  • Other income remained negative at Rs.(12) Cr due to net foreign exchange losses, adding to margin pressure.
  • Finance costs increased 444.6% YoY and 29.2% QoQ, reflecting the full quarter's interest on acquisition debt.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.